Table 1. Impact of spatial normalization for [18F]MNI-659 striatal quantification.
| [18F]MNI-659 BPND | |||||
|---|---|---|---|---|---|
| WT | HET | Δ (Genotype) | 95% CI of diff | Effect size d | |
| MRI template | 1.86 ± 0.20 | 1.06 ± 0.24 | 0.80 (42.9%)**** | +0.533 to +0.962 | 3.62 |
| PET template | 1.93 ± 0.24 | 1.32 ± 0.13 | 0.61 (31.8%)**** | +0.434 to +0.863 | 3.16 |
| CT template | 1.86 ± 0.29 | 0.98 ± 0.32 | 0.88 (47.3%)**** | +0.588 to + 1.030 | 2.88 |
| Δ (PET—MRI) | 0.07 (3.7%) | 0.25 (23.9%)**** | |||
| Δ (MRI—CT) | 0.00 (0.0%) | 0.08 (7.5%) | |||
| Δ (PET—CT) | 0.07 (3.7%) | 0.34 (34.7%)**** | |||
Δ (PET—MRI), difference between MRI and PET template-based spatial normalizations; Δ (MRI—CT), difference between MRI and CT template-based spatial normalizations; Δ (PET—CT), difference between PET and CT template-based spatial normalizations; Δ (Genotype), difference between HET and WT Q175 mice; CI of diff, confidence intervals of difference; WT, wild-type; HET, heterozygous.
****p < 0.0001.